ERBB2 and triple-negative breast carcinoma: Moreover, by altering aptamers that target different cancer cells (e.g., Her2 positive breast cancer cells, triple negative breast cancer cells, non-small cell lung cancer cells, osteosarcoma cells, and so on), the personalized paclitaxel derivatives could be developed for the patients with the according cancer types.